Physicians' Academy for Cardiovascular Education

SGLT2 inhibition in CKD: Discussing the key questions and evidence

Meeting report with presentation slides and video of a PACE-CME symposium held during ERA-EDTA 2019 in Budapest, Hungary on the role of SGLT2i in kidney disease

Underlying mechanisms of nephroprotective effects with SGLT2i in CKD

10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD
Prof. Fioretto discusses possible underlying mechanisms of the nephroprotective effects of SGLT2i, as observed in large clinical trials.

Prof. Fioretto discusses possible underlying mechanisms of the nephroprotective effects of SGLT2i, as observed in large clinical trials.

The clinical landscape of managing patients with CKD: Where are we now and what can we expect?

10' education - June 14, 2019 - ERA-EDTA 2019 - Will Herrington, MD
Dr. Herrington summarizes key randomized data from completed large placebo-controlled SGLT2-inhibitor trials and describes ongoing SGLT2i trials in diabetes, renal and HF populations.

Dr. Herrington summarizes key randomized data from completed large placebo-controlled SGLT2-inhibitor trials and describes ongoing SGLT2i trials in diabetes, renal and HF populations.

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD
Prof. Agarwal discusses the current standard of care in diabetic kidney disease and the evidence of how SGLT2 inhibitors can contribute to protect the kidney in DKD.

ERA-EDTA 2019 Prof. Agarwal discusses the current standard of care in diabetic kidney disease and the evidence of how SGLT2 inhibitors can contribute to protect the kidney in DKD.

Slides: The clinical landscape of managing patients with CKD: Where are we now and what can we expect?

Slides (presentation) - July 3, 2019 - Will Herrington, MD – Oxford, United Kingdom - CME symposium held during ERA EDTA 2019
This lecture by dr. Will Herrington was part of a CME-accredited symposium

Slides as educational service to PACE members and meeting participants

Slides: The knowns and unknowns of SGLT2 inhibition in CKD

Slides (presentation) - July 3, 2019 - Paola Fioretto, MD – Padua, Italy - CME symposium held during ERA EDTA 2019
This lecture by prof. Paola Fioretto was part of a CME-accredited symposium

Slides as educational service to PACE members and meeting participants

Slides: Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

Slides (presentation) - July 3, 2019 - Rajiv Agarwal, MD - Indianapolis, IN, USA - CME symposium held during ERA EDTA 2019
This lecture by prof. Rajiv Agarwal was part of a CME-accredited symposium

Slides as educational service to PACE members and meeting participants

SGLT2 inhibition in CKD: Discussing the key questions and evidence

10' Education

Underlying mechanisms of nephroprotective effects with SGLT2i in CKD

10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD

The clinical landscape of managing patients with CKD: Where are we now and what can we expect?

10' education - June 14, 2019 - ERA-EDTA 2019 - Will Herrington, MD

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD
SGLT2 inhibition in CKD: Discussing the key questions and evidence

Presentation Slides

Slides: The clinical landscape of managing patients with CKD: Where are we now and what can we expect?

Slides (presentation) - July 3, 2019 - Will Herrington, MD – Oxford, United Kingdom - CME symposium held during ERA EDTA 2019

Slides: The knowns and unknowns of SGLT2 inhibition in CKD

Slides (presentation) - July 3, 2019 - Paola Fioretto, MD – Padua, Italy - CME symposium held during ERA EDTA 2019

Slides: Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

Slides (presentation) - July 3, 2019 - Rajiv Agarwal, MD - Indianapolis, IN, USA - CME symposium held during ERA EDTA 2019